title: The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk.
abstract: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomized, double-blind, placebo-controlled trial designed to test the hypothesis that treatment with pravastatin will diminish risk of subsequent major vascular events in a cohort of men and women (70 to 82 years old) with preexisting vascular disease or significant risk of developing this condition. Five thousand eight hundred four men and women in addition to receiving advice on diet and smoking, have been randomized equally to treatment with 40 mg pravastatin/day or matching placebo in 3 centers (Cork, Ireland, Glasgow, Scotland, and Leiden, The Netherlands). Following an average 3.5-year intervention period, a primary assessment will be made of the influence of this therapy on major vascular events (a combination of coronary heart disease, death, nonfatal myocardial infarction, and fatal and nonfatal stroke). A number of additional analyses will also be conducted on the individual components of the primary end point, on men, on women, and on subjects with and without previous evidence of vascular disease. Finally, an assessment will be made of the effects of treatment on cognitive function, disability, hospitalization or institutionalization, vascular mortality, and all-cause mortality.
authors.affiliation: University of Glasgow, Scotland. JS4N@clinmed.gla.ac.uk
authors.forename: J
authors.initials: J
authors.lastname: Shepherd
authors.forename: G J
authors.initials: GJ
authors.lastname: Blauw
authors.forename: M B
authors.initials: MB
authors.lastname: Murphy
authors.forename: S M
authors.initials: SM
authors.lastname: Cobbe
authors.forename: E L
authors.initials: EL
authors.lastname: Bollen
authors.forename: B M
authors.initials: BM
authors.lastname: Buckley
authors.forename: I
authors.initials: I
authors.lastname: Ford
authors.forename: J W
authors.initials: JW
authors.lastname: Jukema
authors.forename: M
authors.initials: M
authors.lastname: Hyland
authors.forename: A
authors.initials: A
authors.lastname: Gaw
authors.forename: A M
authors.initials: AM
authors.lastname: Lagaay
authors.forename: I J
authors.initials: IJ
authors.lastname: Perry
authors.forename: P W
authors.initials: PW
authors.lastname: Macfarlane
authors.forename: A E
authors.initials: AE
authors.lastname: Meinders
authors.forename: B J
authors.initials: BJ
authors.lastname: Sweeney
authors.forename: C J
authors.initials: CJ
authors.lastname: Packard
authors.forename: R G
authors.initials: RG
authors.lastname: Westendorp
authors.forename: C
authors.initials: C
authors.lastname: Twomey
authors.forename: D J
authors.initials: DJ
authors.lastname: Stott
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D017035:Pravastatin / Q000627:therapeutic use*; D011446:Prospective Studies; D020521:Stroke / Q000517:prevention & control*
chemical_list: D000924:Anticholesteremic Agents; D017035:Pravastatin